Every material Form 8-K VIEMED HEALTHCARE, INC. has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Viemed reported record third-quarter 2026 net revenue of $80.7 million, up 12.2% from a year earlier, and net income attributable to the company of $4.6 million, or $0.11 per diluted share, versus $0.09 a year earlier. It raised the low end of its 2026 revenue guidance to $316 million to $320 million but lowered the top of its Adjusted EBITDA range to $64 million to $66 million from $64 million to $68 million, so shareholders see higher revenue and profit alongside a narrower EBITDA outlook.
Q3 2026 net revenue $80.7 million, up $8.8 million or 12.2% year over year
Net income attributable to Viemed $4.6 million, or $0.11 per diluted share, versus $0.09 in Q3 2025
Adjusted EBITDA $17.1 million, up 5.8% year over year, with a margin of 21.1% of net revenue
2026 guidance: revenue $316 million to $320 million (low end raised from $314 million); Adjusted EBITDA $64 million to $66 million (high end lowered from $68 million)
VieMed Healthcare furnished an August 2026 investor presentation under Regulation FD that reports second-quarter 2026 net revenue of $78.1 million, up 24% from a year earlier, and Adjusted EBITDA of $13.7 million. The deck restates full-year 2026 guidance and says the board authorized a new share repurchase program of up to 5% of shares outstanding.
2Q 2026 net revenue was $78.1 million, up 24% year over year; Adjusted EBITDA was $13.7 million.
2026 guidance: net revenue of $314 million to $320 million and Adjusted EBITDA of $64 million to $68 million.
New share repurchase program authorized for up to 5% of shares outstanding; 680,802 shares were bought in 1H 2026 for $6.5 million.
Net debt was effectively zero as of June 30, 2026, with $46 million of unfunded credit facility commitments.
Viemed Healthcare reported second-quarter 2026 net revenue of $78.1 million, a company record and up 23.9% from a year earlier, while net income attributable to the company fell to $2.8 million from $3.2 million. The company raised the low end of its full-year net revenue guidance but cut its Adjusted EBITDA guidance by $1 million at both ends of the range, to $64 million to $68 million.
Q2 2026 net revenue was $78.1 million, up $15.0 million, or 23.9%, from the prior-year quarter.
Net income attributable to Viemed was $2.8 million, or $0.07 per diluted share, versus $3.2 million in Q2 2025.
Adjusted EBITDA was $13.7 million, down 4.0% year over year; the prior-year period included a $1.0 million non-recurring gain.
2026 guidance: net revenue $314 million to $320 million (previously $312 million to $320 million); Adjusted EBITDA $64 million to $68 million (previously $65 million to $69 million).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every VIEMED HEALTHCARE, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →